Table 6.

Summary of quantitative follow up survey results, Rwanda (source: LIAT survey, unless otherwise noted)

	Definition	QC Group	IcSCI Group	NI Group
Primary objective*	CHWs have usable and quality essential medicines available when needed for appropriate treatment of pneumonia and other common diseases of childhood	63% of CHWs had all 5 products in stock on DOV†, significantly better than comparison group (P < 0.001)	45% of CHWs had all 5 products in stock on DOV†	38% of CHWs had all 5 products in stock on DOV†
Product flow*	Clear procedures and processes for inventory management, distribution, and storage exist and are executed as expected	100% of CCs reported that they picked up products for all CHWs in their cell after every monthly meeting	91% of CCs reported that they picked up products for all CHWs in their cell after every monthly meeting	N/A
		93% of CHWs reported that they received products regularly	93% of CHWs reported that they received products regularly	85% of CHWs reported that they received products regularly
		95% of CHWs reported that they received products from CCs	93% of CHWs reported that they received products from CCs	26% of CHWs reported that they received products from CCs (majority receive from CHW Supervisor – 63%)
Data flow*	Logistics (consumption and stock levels) data are available and usable for supply chain decision making, management, monitoring, and problem solving	81% CHWs reporting on time	86% CHWs reporting on time	N/A
		97% of HCPM have copies of any resupply worksheets submitted by CCs at the last monthly meeting	92% of HCPM have copies of any resupply worksheets submitted by CCs at the last monthly meeting	N/A
			% of CCs who presented complete RSWs without any calculation errors during monthly health center meetings improved from average 77% for the three districts in the first quarter, to 98% in the final quarter (source: IcSCI indicators database)	N/A
		CCs had key QC tools completed with data collected to use for quality improvement: • 93% CCs could show the bar graph for last month of QIT • 91% of CCs could show the tally sheet for last month of QIT • 97% of CCs who could show tally sheets and bar graphs had agreement between the two records for the last month of the intervention		N/A
		83–98% of CHWs had stock cards on day of visit for amoxicillin, ORS, zinc, Primo Rouge, and RDTs, significantly better than comparison group for same products	83–95% of CHWs had stock cards on day of visit for all five iCCM products, significantly better than comparison group for same products	65–83% of CHWs with stock cards on day of visit for all five iCCM products
		36% of CHWs had accurate stock card for all 6 product	33% of CHWs had accurate stock card for all 6 products	18% of CHWs had accurate stock card for all 6 products
Effective people	Management processes and skills exist; Teamwork takes places across multiple levels, using data for problem solving; CHWs are motivated and recognized for SC accomplishments	High levels of competency were found in completing RSWs; 80% of CCs were able to enter correct quantities required	High levels of competency were found in completing RSWs; 86% of CCs were able to enter correct quantities required	N/A
		77% of HCs could show their completed Q3 action plan	All districts showed significant improvements in 3 key SC indicators across 4 implementation quarters (source: IcSCI indicators database)	N/A

ACT – artemisin–based combination therapy, CC – Cell Coordinator, iCCM – community case management, CHW – community health worker, DOV – day of visit, HCPM – Health Center Pharmacy Manager, IcSCI – Incentives for Community Supply Chain Improvement, QC – Quality Collaboratives, NI – non intervention comparison group, ORS – oral rehydration solution, Q3 – 3rd quartile, QIT – Quality Improvement Team, RDT – rapid diagnostic tests (malaria), RSW – resupply worksheet, SC – supply chain

*Comparison group data available for Primary Objective, and for select Product Flow and Data Flow data points, other data points in the table relate specifically to the interventions and are not relevant in the comparison group.

†Products include amoxicillin, 150 mg, ORS, zinc 10mg, Primo Rouge (ACT 1 × 6), Primo Jaune (ACT 2 × 6).